EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rethinking the Diabetes–Cardiovascular Disease Continuum: Toward Integrated Care

Alfredo Caturano iD, Cassandra Morciano, Katarzyna Zielińska, Vincenzo Russo iD, Marco Alfonso Perrone iD, Cesare Celeste Berra iD, Caterina Conte iD

Journal of Clinical Medicine · 22.09.2025 · 14 (18) · 6678

DOI: 10.3390/jcm14186678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 22.09.2025. Verfasst von Alfredo Caturano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes mellitus (T2D) and cardiovascular disease (CVD) are not merely coexisting epidemics but co-evolving manifestations of a shared cardiometabolic continuum. Despite advances in glycemic, lipid, and blood pressure control, residual cardiovascular risk remains high, underscoring the limitations of siloed approaches. In this perspective, we argue for reframing T2D and CVD as interconnected conditions driven by inflammation, adipose tissue dysfunction, and organ crosstalk. Beyond metformin, which remains foundational, several glucose-lowering drug classes are now evaluated not only for glycemic control but also for their cardiovascular and renal impact. Landmark trials and recent meta-analyses confirm that sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists improve cardiorenal outcomes. More recently, tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, has shown unprecedented efficacy in weight and glucose management, with potential to further transform cardiometabolic risk reduction. Yet enthusiasm for these therapies must be tempered by heterogeneity of response, treatment costs, and inequitable access. Integrated care models, supported by multidisciplinary teams, digital health tools, and value-based reimbursement, are essential to close the gap between trial efficacy and real-world outcomes. Attention to sex, age, ethnicity, and comorbidity profiles is critical to ensure equity, as is the adaptation of strategies to low- and middle-income countries where the burden of cardiometabolic disease is rapidly rising. Ultimately, advancing cardiometabolic medicine requires not only novel therapies but also a unifying framework that integrates biology, behavior, economics, and health systems to deliver the right treatment to the right patient at the right time.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2icardiometabolic continuumcardiovascular diseasecardiovascular-kidney-metabolic syndrometirzepatidetype 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma University, 00166 Rome, Italy.
  • Centro Malattie Endocrine e Metaboliche, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Scanmed Medical Center in Krakow, 30150 Krakow, Poland.
  • Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
  • Division of Cardiology, Department of Medical Translational Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Department of Cardiology and CardioLab, University of Rome Tor Vergata, 00133 Rome, Italy.

ORCID-Profile: Alfredo Caturano, Vincenzo Russo, Marco Alfonso Perrone, Cesare Celeste Berra, Caterina Conte

Förderung

  • Italian Ministry of Health

Zitieren

APA

Caturano, A., Morciano, C., Zielińska, K., Russo, V., Perrone, M. A., Berra, C. C., & Conte, C. (2025). Rethinking the Diabetes–Cardiovascular Disease Continuum: Toward Integrated Care. Journal of Clinical Medicine, 14(18), 6678. https://doi.org/10.3390/jcm14186678

Vancouver

Caturano A, Morciano C, Zielińska K, Russo V, Perrone MA, Berra CC, et al. Rethinking the Diabetes–Cardiovascular Disease Continuum: Toward Integrated Care. Journal of Clinical Medicine. 2025;14(18):6678. doi:10.3390/jcm14186678

BibTeX
@article{Caturano2025,
  author = {Caturano, Alfredo and Morciano, Cassandra and Zielińska, Katarzyna and Russo, Vincenzo and Perrone, Marco Alfonso and Berra, Cesare Celeste and Conte, Caterina},
  title = {Rethinking the Diabetes–Cardiovascular Disease Continuum: Toward Integrated Care},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {18},
  pages = {6678},
  doi = {10.3390/jcm14186678}
}
Kostenlos starten →